CL King reiterates a Buy rating and $64 price target on Boston Scientific shares ahead of its Investor Day event on September 20, at which the firm expects the company to outline its financial targets for the next three years. The company has one of the most compelling pipelines across the MedTech industry, which should drive near- and long-term shareholder value creation, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BSX: